Thallion Completes Patient Enrollment of Phase II SHIGATEC Trial

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection. Dr. Allan Mandelzys, Thallion’s CEO, said in a statement, “The timely completion of patient recruitment and the two month patient follow [...]

Thallion in $150-million pact to develop Shigamabs

Thallion Pharmaceuticals (TSX:TLN) is teaming up with LFB Biotechnologies of France to develop Shigamabs, Thallion’s product candidate for the treatment of Shigatoxin-producing bacterial, or STEC, infection. The accord, which is expected to close in the first quarter, provides for immediate funding by LFB of costs associated with re-initiating the Shigamabs program. In a statement, Thallion [...]

Thallion financing a potential watershed

Thallion Pharmaceuticals’ recent $8.85-million non-dilutive financing could turn out to be a pivotal event for cash-strapped Canadian healthcare companies facing the grim prospects of raising capital in today’s tough public equity markets. The deal, completed in July with Premium Brands Income Fund, essentially involved Thallion transferring all of its assets, with the exception of its [...]